# OnCo record keynote-811 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-811/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-811", "NCT03615326" ;
  schema:name "KEYNOTE-811"@en ;
  schema:description "KEYNOTE-811 showed that adding the immunotherapy pembrolizumab to trastuzumab and chemotherapy shrank HER2-positive stomach cancers more often and kept them under control for longer, with the gain concentrated in tumours that also express PD-L1."@en ;
  schema:url <https://onco.cc/trials/keynote-811/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03615326> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/gastric-her2-positive/>, <https://onco.cc/cancers/gastric/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/yelena-janjigian/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-811-janjigian-lancet-2023/> .